Price target
18.740.00 0.00%
The 9 analysts offering 1 year price forecasts for LC8 have a max estimate of — and a min estimate of —.
Analyst rating
Based on 9 analysts giving stock ratings to LC8 in the past 3 months.
EPS
0.00
Reported
Estimate
Reported
Estimate
Surprise
Revenue
0.00
Reported
Estimate
Reported
Estimate
Surprise
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Frequently Asked Questions
LC8 EPS for the last quarter is −0.40 EUR despite the estimation of −0.09 EUR. In the next quarter EPS is expected to reach −0.04 EUR. Track more of CALLIDITAS THERAPEUTICS AB financials and stay on top of what is up with the company.
In the next quarter CALLIDITAS THERAPEUTICS AB revenue is expected to reach 40.56 M EUR. Check out CALLIDITAS THERAPEUTICS AB revenue and earnings and make informed decisions.
According to analysts, LC8 price target is 18.74 EUR with a max estimate of 23.67 EUR and a min estimate of 15.52 EUR. Check if this forecast comes true in a year, meanwhile watch CALLIDITAS THERAPEUTICS AB stock price chart and keep track of the current situation with LC8 news and stock market news.
We've gathered opinions of 9 analysts rating LC8 stock in the past 3 months. Most of them backed up the neutral trend, and after taking into account other opinions, the overall rating was calculated as neutral. Note that it's not a trading advice — your own analysis is still required.